Literature DB >> 22670444

[Screening strategy and diagnostic criteria for gestational diabetes. Proposals of the GGOLFB].

J F Vanderijst, F Debieve, F Doucet, P Emonts, S Haumont, C Hubinont, C Kirkpatrick, J C Philips, A Pintiaux, P Rousseau, G Senterre, B Vandeleene, F Féry.   

Abstract

For nearly 50 years, the strategy of screening and the diagnostic criteria for gestational diabetes have been the subject of endless controversies. They differ between countries and from one center to another, mainly because of the lack of hard data allowing to define glycemic thresholds at which a therapeutic management is needed. Recently, a large observational study has demonstrated the existence of a robust relationship between maternal blood sugar and several fetomaternal perinatal complications. This relationship is linear, with no clear threshold that would define gestational diabetes unambiguously. Meanwhile, two randomized intervention trials have shown that the therapeutic management of mild gestational diabetes was associated with improved perinatal outcomes. Based on these data, the "International Association of Diabetes and Pregnancy Study Group" (IADPSG) released new recommendations on screening methods and diagnostic criteria for gestational diabetes. Although already endorsed by several international associations and implemented in some countries, these recommendations still raise questions and criticisms. This is why the "Groupement des Gynécologues Obstétriciens de Langue Française de Belgique" (GGOLFB) organized a meeting between diabetologists and gynecologists which allowed to reach a consensus on the strategy that we intend to implement in our respective centers. The purpose of this paper is to briefly overview the recent advances in gestational diabetes and more particularly to make our key conclusions known to the medical community. This will enable the standardization of the management of gestational diabetes in the French-speaking part of Belgium.

Entities:  

Mesh:

Year:  2012        PMID: 22670444

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN: 0370-629X


  5 in total

1.  A proposal for the use of uniform diagnostic criteria for gestational diabetes in Europe: an opinion paper by the European Board & College of Obstetrics and Gynaecology (EBCOG).

Authors:  Katrien Benhalima; Chantal Mathieu; Peter Damm; André Van Assche; Roland Devlieger; Gernot Desoye; Rosa Corcoy; Tahir Mahmood; Jacky Nizard; Charles Savona-Ventura; Fidelma Dunne
Journal:  Diabetologia       Date:  2015-05-08       Impact factor: 10.122

2.  Evolution of maternal and neonatal outcomes before and after the adoption of the IADPSG/WHO guidelines in Belgium: A descriptive study of 444,228 pregnancies.

Authors:  Philippe Oriot; Charlotte Leroy; Virginie Van Leeuw; Jean Christophe Philips; Jean François Vanderijst; Aline Vuckovic; Elena Costa; Christian Debauche; Frederic Chantraine
Journal:  Heliyon       Date:  2022-04-12

3.  Screening for pregestational and gestational diabetes in pregnancy: a survey of obstetrical centers in the northern part of Belgium.

Authors:  Katrien Benhalima; Paul Van Crombrugge; Roland Devlieger; Johan Verhaeghe; Ann Verhaegen; Luc De Catte; Chantal Mathieu
Journal:  Diabetol Metab Syndr       Date:  2013-11-11       Impact factor: 3.320

4.  Glucose intolerance after a recent history of gestational diabetes.

Authors:  Katrien Benhalima; Liesbeth Leuridan; Peggy Calewaert; Roland Devlieger; Johan Verhaeghe; Chantal Mathieu
Journal:  Int J Endocrinol       Date:  2014-08-07       Impact factor: 3.257

5.  The Belgian Diabetes in Pregnancy Study (BEDIP-N), a multi-centric prospective cohort study on screening for diabetes in pregnancy and gestational diabetes: methodology and design.

Authors:  Katrien Benhalima; Paul Van Crombrugge; Johan Verhaeghe; Sofie Vandeginste; Hilde Verlaenen; Chris Vercammen; Els Dufraimont; Christophe De Block; Yves Jacquemyn; Farah Mekahli; Katrien De Clippel; Roland Devlieger; Chantal Mathieu
Journal:  BMC Pregnancy Childbirth       Date:  2014-07-11       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.